For investors

Lexi Ventures invests in early stage gene tech companies.

This focus is rooted in these beliefs.

Gene tech startups aim to cure many of the worst and most expensive diseases, improving happiness and reducing healthcare needs. Other gene tech startups will enable plants and microbes to produce newer and better things while sustaining the natural environment.

Lexi Ventures seeks to build a venture capital investment portfolio concentrated in gene tech companies from their early stages.

For startups

Lexi Ventures provides seed stage funding for startups applying or enabling genomics or synthetic biology.

Most investments that Lexi Ventures considers are best described using the key words DNA, RNA, proteins, or cells.

Lexi Ventures exclusively considers companies with a US corporate structure, and usually companies headquartered in the US.

Lexi Ventures occasionally considers pre-seed funding rounds of particularly promising companies and post-seed rounds with particularly attractive terms.

Please connect if you are working on any of these.

With great respect to companies and entrepreneurs in adjacent tech, Lexi Ventures does not invest in:

Jonah Probell

Managing Partner

Jonah manages the investments for Lexi Ventures. Prior to finance, he held engineering, executive, and founder roles in 7 startups. He achieved 2 IPOs, 16 granted patents and wrote 2 books.

Jonah believe in a rational, dispassionate, methodical approach to investing for maximum realized IRR. This approach grew from a decade of experience building patent portfolios.

Jonah has a lifelong interest in science, engineering, economics, philosophy, and the history of human technological development.

LinkedIn